GSK Investigational Site
Santo André, São Paulo, 09060-650, Brazil
NCT Number: NCT02757950
The purpose of this study is to assess the safety of RefortrixTM (Tdap) when administered during pregnancy in a maternal immunization program in Brazil.
Looking for future studies?
Notify Me18 year–45 year
Female
Observational
Santo André, São Paulo, 09060-650, Brazil
In this retrospective cohort study the safety of RefortrixTM (Tdap) administered during pregnancy as part of the National immunization program in Brazil will be assessed by comparing the risk of pre-defined adverse events before and after introduction of the RefortrixTM (Tdap) maternal immunization program.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for the Exposed cohort:
Inclusion criteria
for the Unexposed cohort:
Exclusion criteria
Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
Time frame: After week 27 of pregnancy
Gestational diabetes was defined as: Onset or first recognition of abnormal glucose tolerance during pregnancy (the diagnosis is based on administration of glucose challenge test at 24-28 weeks of gestation). Includes Class A1: Euglycaemia achieved with diet and/or exercise and Class A2: Euglycaemia achieved with medication.
Time frame: After week 27 of pregnancy
Pregnancy-related hypertension is defined as:
Blood pressure systolic higher than (>) 140 and/or diastolic > 90 millimetre of mercury (mmHg), documented in at least two separate measurements after 20 weeks of gestation, without proteinuria or other stigmata of pre-eclampsia, and returning to normal post-partum. Hypertension usually resolves by 12 weeks post-partum, included pre-eclampsia, eclampsia and haemolysis elevated liver enzymes low platelet (HELLP) Syndrome for this study.
Time frame: After week 27 of pregnancy
Pregnancy vaginal hemorrhage is defined as: excessive blood loss after delivery i.e. estimated blood loss in excess of 500 milliliters (ml) after vaginal delivery and estimated blood loss in excess of 1000 ml after Caesarean delivery. The other symptoms are higher than or equal to (≥) 10 percent (%) drop in hematocrit, need for blood transfusion, symptomatic hypotension, dizziness, pallor and oliguria.
Vaginal or intrauterine hemorrhage that encompasses antepartum (i.e. bleeding from the genital tract after 24 weeks of gestation), intrapartum, and postpartum bleeding (i.e. within 24 hours post-delivery).
A major obstetric hemorrhage is defined as blood loss from uterus or genital tract >1500 ml or a decrease.
Time frame: From week 27 up to week 37 of pregnancy
Preterm birth is defined as: Birth before 37 weeks of gestation.
Time frame: After week 27 of pregnancy
Small for gestational age is defined as: Birth weight less than (<) 10% for infants of same gestational age and gender in same population.
Time frame: After week 27 of pregnancy
Pregnancy-related AEs of interest and neonate-related events are defined as: premature rupture of membranes, preterm premature rupture of membranes, premature uterine contraction, neonatal death, maternal death, still birth, neonatal hypoxic ischaemic encephalopathy.
Time frame: From week 27 of pregnancy up to birth
Congenital anomalies include morphological, functional, chromosomal or genetic anomalies, regardless of whether detected at birth or not, the foetus is delivered dead or alive, or defects are identified by prenatal ultrasound, amniocentesis or examination of the products of conception.
Time frame: After week 27 of pregnancy
Pregnancy related AEs include: gestational diabetes, pregnancy-related hypertension, pre-eclampsia, eclampsia, HELLP Syndrome and pregnancy hemorrhage. Birth outcomes include: preterm birth and small for gestational age.
GlaxoSmithKline
Industry
A Post-marketing, Observational, Retrospective, Cohort Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07444502
Actinomycetales Infections, Bacterial Infections
Bangkok, Thailand
View Trial DetailsNCT02118961
Actinomycetales Infections, Bacterial Infections
Fukuoka, Japan
View Trial DetailsNCT03891758
Actinomycetales Infections, Bacterial Infections
Fukuoka, Japan
View Trial DetailsNCT06588530
Actinomycetales Infections, Adult
Paulsboro, New Jersey, United States
View Trial Details